Literature DB >> 25815421

The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.

Jaeyeon Kim1, Donna M Coffey, Lang Ma, Martin M Matzuk.   

Abstract

Although named "ovarian cancer," it has been unclear whether the cancer actually arises from the ovary, especially for high-grade serous carcinoma (HGSC), also known as high-grade serous ovarian cancer, the most common and deadliest ovarian cancer. In addition, the tumor suppressor p53 is the most frequently mutated gene in HGSC. However, whether mutated p53 can cause HGSC remains unknown. In this study, we bred a p53 mutation, p53(R172H), into conditional Dicer-Pten double-knockout (DKO) mice, a mouse model duplicating human HGSC, to generate triple-mutant (TKO) mice. Like DKO mice, these TKO mice develop metastatic HGSCs originating from the fallopian tube. Unlike DKO mice, however, even after fallopian tubes are removed in TKO mice, ovaries alone can develop metastatic HGSCs, indicating that a p53 mutation can drive HGSC arising from the ovary. To confirm this, we generated p53(R172H)-Pten double-mutant mice, one of the genetic control lines for TKO mice. As anticipated, these double-mutant mice also develop metastatic HGSCs from the ovary, verifying the HGSC-forming ability of ovaries with a p53 mutation. Our study therefore shows that ovaries harboring a p53 mutation, as well as fallopian tubes, can be a distinct tissue source of high-grade serous ovarian cancer in mice.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25815421      PMCID: PMC5393339          DOI: 10.1210/en.2014-1977

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  34 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Summaries for patients. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

3.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

Review 4.  The post-reproductive Fallopian tube: better removed?

Authors:  J Dietl; J Wischhusen; S F M Häusler
Journal:  Hum Reprod       Date:  2011-08-16       Impact factor: 6.918

5.  Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.

Authors:  Lucy Gilbert; Olga Basso; John Sampalis; Igor Karp; Claudia Martins; Jing Feng; Sabrina Piedimonte; Louise Quintal; Agnihotram V Ramanakumar; Janet Takefman; Maria S Grigorie; Giovanni Artho; Srinivasan Krishnamurthy
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

Review 6.  Germline TP53 mutations and Li-Fraumeni syndrome.

Authors:  J M Varley
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

Review 7.  Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Authors:  Christopher P Crum; Ronny Drapkin; David Kindelberger; Fabiola Medeiros; Alexander Miron; Yonghee Lee
Journal:  Clin Med Res       Date:  2007-03

8.  Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

Authors:  Russell Hogg; Michael Friedlander
Journal:  J Clin Oncol       Date:  2004-04-01       Impact factor: 44.544

9.  Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression.

Authors:  Marie-Noëlle Laguë; Marilène Paquet; Heng-Yu Fan; M Johanna Kaartinen; Simon Chu; Soazik P Jamin; Richard R Behringer; Peter J Fuller; Andrew Mitchell; Monique Doré; Louis M Huneault; Joanne S Richards; Derek Boerboom
Journal:  Carcinogenesis       Date:  2008-08-06       Impact factor: 4.944

10.  Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth.

Authors:  W M Baarends; J T Uilenbroek; P Kramer; J W Hoogerbrugge; E C van Leeuwen; A P Themmen; J A Grootegoed
Journal:  Endocrinology       Date:  1995-11       Impact factor: 4.736

View more
  37 in total

1.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

2.  Screening for ovarian cancer: imaging challenges and opportunities for improvement.

Authors:  K B Mathieu; D G Bedi; S L Thrower; A Qayyum; R C Bast
Journal:  Ultrasound Obstet Gynecol       Date:  2018-03       Impact factor: 7.299

3.  Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.

Authors:  Mingxin Shi; Allison E Whorton; Nikola Sekulovski; Marilène Paquet; James A MacLean; Yurong Song; Terry Van Dyke; Kanako Hayashi
Journal:  Biol Reprod       Date:  2020-04-24       Impact factor: 4.285

4.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Authors:  Josephine Walton; Julianna Blagih; Darren Ennis; Elaine Leung; Suzanne Dowson; Malcolm Farquharson; Laura A Tookman; Clare Orange; Dimitris Athineos; Susan Mason; David Stevenson; Karen Blyth; Douglas Strathdee; Frances R Balkwill; Karen Vousden; Michelle Lockley; Iain A McNeish
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

5.  Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair.

Authors:  Dana Sherill-Rofe; Oded Raban; Steven Findlay; Dolev Rahat; Irene Unterman; Arash Samiei; Amber Yasmeen; Zafir Kaiser; Hellen Kuasne; Morag Park; William D Foulkes; Idit Bloch; Aviad Zick; Walter H Gotlieb; Yuval Tabach; Alexandre Orthwein
Journal:  NAR Cancer       Date:  2022-04-08

Review 6.  The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.

Authors:  Xiyin Wang; Mircea Ivan; Shannon M Hawkins
Journal:  Gynecol Oncol       Date:  2017-08-31       Impact factor: 5.482

7.  In Utero Exposure to Benzo[a]pyrene Induces Ovarian Mutations at Doses That Deplete Ovarian Follicles in Mice.

Authors:  Ulrike Luderer; Matthew J Meier; Gregory W Lawson; Marc A Beal; Carole L Yauk; Francesco Marchetti
Journal:  Environ Mol Mutagen       Date:  2018-12-21       Impact factor: 3.216

8.  MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread.

Authors:  Pui-Wah Choi; Wai Wing So; Junzheng Yang; Shubai Liu; Ka Kui Tong; Kin Ming Kwan; Jamie S-L Kwok; Stephen K W Tsui; Shu-Kay Ng; Karen H Hales; Dale B Hales; William R Welch; Christopher P Crum; Wing-Ping Fong; Ross S Berkowitz; Shu-Wing Ng
Journal:  Oncogene       Date:  2020-03-25       Impact factor: 9.867

Review 9.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Authors:  David D Bowtell; Steffen Böhm; Ahmed A Ahmed; Paul-Joseph Aspuria; Robert C Bast; Valerie Beral; Jonathan S Berek; Michael J Birrer; Sarah Blagden; Michael A Bookman; James D Brenton; Katherine B Chiappinelli; Filipe Correia Martins; George Coukos; Ronny Drapkin; Richard Edmondson; Christina Fotopoulou; Hani Gabra; Jérôme Galon; Charlie Gourley; Valerie Heong; David G Huntsman; Marcin Iwanicki; Beth Y Karlan; Allyson Kaye; Ernst Lengyel; Douglas A Levine; Karen H Lu; Iain A McNeish; Usha Menon; Steven A Narod; Brad H Nelson; Kenneth P Nephew; Paul Pharoah; Daniel J Powell; Pilar Ramos; Iris L Romero; Clare L Scott; Anil K Sood; Euan A Stronach; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

10.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.